Trial Profile
Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover, Phase I Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2014
Price :
$35
*
At a glance
- Drugs Linagliptin/metformin (Primary) ; Linagliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 07 May 2014 New trial record
- 22 Apr 2014 Primary endpoint 'Peak-drug-concentration' has been met.
- 22 Apr 2014 Primary endpoint 'Drug-bioavailability' has been met.